Influence of systemic inflammation on efficiency of antiplatelet therapy in PAOD patients

By Ziegler S.  

Annals of Hematology, Vol. 83, Iss. 2, 2004-02 ,pp. : 92-94

Springer Publishing Company

Access to resources Recommend Favorite

Are anti-ribosomal P protein antibodies relevant in systemic lupus erythematosus?

By Kiss Emese  

Clinical Reviews in Allergy and Immunology, Vol. 32, Iss. 1, 2007-02 ,pp. : 37-46

Humana Press, Inc

Access to resources Recommend Favorite

Is reduced systemic heparinization justified with heparin-bonded bypass circuits in cardiac surgery?--Experience with and without aprotinin

By Kipfer B.   Englberger L.   Gygax E.   Nydegger U.   Carrel T.  

Transfusion and Apheresis Science, Vol. 29, Iss. 1, 2003-08 ,pp. : 17-24

Elsevier

Access to resources Recommend Favorite

Was it justified?

By Heron John  

Australasian Physical & Engineering Sciences in Medicine, Vol. 34, Iss. 1, 2011-04 ,pp. : 1-3

Springer Publishing Company

Access to resources Recommend Favorite

Antiplatelet Therapies: Aspirin at the Heart of New Directions

By  

Cardiovascular & Haematological Disorders - Drug Targets(Formerly Current Drug Targets - Cardiovascular & Hematological Disorders), Vol. 13, Iss. 3, 2013-12 ,pp. : 173-184

Bentham Science Publishers

Access to resources Recommend Favorite